Robot-Assisted Surgery: A Promising Tool Yet to Prove Superiority

By HEOR Staff Writer

September 7, 2023

Robot-Assisted Surgery (RAS) is a technologically advanced form of minimally invasive surgery, offering a higher degree of precision compared to traditional laparoscopic methods. RAS allows surgeons to control the instruments of the robotic system remotely, providing a further minimally invasive surgical option for patients.

According to the World Health Organization (WHO), there are currently 19 known manufacturers of robotic systems designed to aid in surgical procedures. The most widely used among these is the da VinciĀ® Surgical System.

The Austrian Institute for Health Technology Assessment (AIHTA) report focused on the use of RAS in thoracic and visceral surgery. Thoracic surgery primarily treats conditions of the lungs, chest wall, and diaphragm, while visceral surgery focuses on diseases of abdominal organs, the gastrointestinal tract, endocrine organs, the abdominal wall, and the peritoneum.
However, the report revealed mixed results regarding the effectiveness and safety of RAS. While RAS claims to reduce readmissions and shorten hospital stays, no statistically significant differences were detected compared to laparoscopic or open procedures.

On the positive side, RAS resulted in decreased blood loss in certain procedures and fewer postoperative complications in others. However, it also tends to have a higher mean cost per procedure than conventional surgical methods.

The report concluded that while RAS might present potential advantages for certain indications and outcomes, most of the claimed benefits could not be materialised. Moreover, the financial and environmental implications must be considered in purchasing decisions.

In conclusion, while RAS is a promising tool in the field of surgery, more comprehensive studies with larger sample sizes and longer follow-up times are needed to conclusively determine its superiority over traditional surgical methods.

Reference url

Recent Posts

Strategic Avalere Health Appointments Enhance Leadership in Navigating US Healthcare Policy Changes

By João L. Carapinha

December 17, 2025

Avalere Health strengthened its appointments, with Matt Kazan returning as Senior Vice President of Policy, where he previously served as a former top advisor on the US Senate Committee on Finance, and he will now lead the policy team amid changes like the Inflation Reduction Act. Laura Housman, ...
Accelerating Tec-Dara Multiple Myeloma Therapy Review: A Game Changer for Patients

By HEOR Staff Writer

December 16, 2025

Accelerating Review for Transformative Multiple Myeloma Therapy The U.S. Food and Drug Administration (
CHMP Meeting Highlights: December 2025 Advances in New Medicines Approvals
The CHMP meeting highlights from December 2025 reveal major advancements in drug approvals. What were the key outcomes of the EMA's Committee for Medicinal Products for Human Use session held December 8-11? The committee recommended seven new medicines for approval. These target critical areas li...